IL-21-primed autologous CD8-positive T-lymphocytes

IL-21-primed autologous CD8-positive T-lymphocyte therapy is an investigational adoptive cell therapy developed by the M.D. Anderson Cancer Center for the treatment of recurrent or platinum-resistant ovarian cancer. The therapeutic process involves the isolation of a patient's own CD8+ T cells, which are then primed ex vivo with Interleukin-21 (IL-21) to induce a central memory phenotype and enhance their cytotoxic potential against ovarian cancer antigens. Once re-infused, these tumor-antigen-specific cytotoxic T lymphocytes (CTLs) are intended to recognize and eliminate malignant cells. In clinical trial settings (such as NCT03318900), this cell therapy is administered following lymphodepleting chemotherapy and in combination with aldesleukin (IL-2) to support T-cell expansion and utomilumab (a 4-1BB agonist) to provide necessary costimulatory signals and improve T-cell persistence.

Other names

CD8-positive T-lymphocyte-M.D. Anderson Cancer Center-ovarian cancerCD-8-positive T-lymphocyte-M.D. Anderson Cancer Center-ovarian cancerCD 8-positive T-lymphocyte-M.D. Anderson Cancer Center-ovarian cancerIL-21-primed CD8+ tumor antigen-specific T cellsAdoptive T-cell TherapyCD8-Positive T-LymphocyteCD-8-Positive T-LymphocyteCD 8-Positive T-Lymphocyte